Theoretical investigations on the structural stability, structural and physical properties, and bonding feature for RuX (X = Si, Ge, Sn) with B20 and B2 phases
Sign Up to like & getrecommendations! Published in 2020 at "Materials today communications"
DOI: 10.1016/j.mtcomm.2020.101116
Abstract: Abstract A systematic first-principles study on the structural features and stabilities, bonding features and related physical properties of ruthenium compounds RuX (X = Si, Ge, Sn) with B20 and B2 configurations including the elastic, electronic… read more here.
Keywords: rux; physical properties; b20; theoretical investigations ... See more keywords
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18057
Abstract: Deferasirox (DFX) is used for the management of iron overload (IOL) in many haematological malignancies including myelofibrosis (MF). The ‘RUX‐IOL’ study retrospectively collected 69 MF patients treated with ruxolitinib (RUX) and DFX for IOL to… read more here.
Keywords: rux dfx; iron overload; management iron; rux ... See more keywords
Review of Ruxolitinib in the Treatment of Atopic Dermatitis
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280221103282
Abstract: Objective To review the pharmacokinetics, efficacy, and safety of a newly approved topical Janus kinase 1 (JAK) inhibitor, ruxolitinib (RUX), in patients with atopic dermatitis (AD). Data Sources A literature search was completed May 1,… read more here.
Keywords: ruxolitinib; review; rux; atopic dermatitis ... See more keywords
Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-115350
Abstract: BACKGROUND Ruxolitinib (RUX), a potent Janus kinase (JAK)1/JAK2 inhibitor, is approved for hydroxyurea (HU)-resistant/-intolerant patients (pts) with polycythemia vera (PV) based on findings from the RESPONSE study (NCT01243944). RUX proved superior to best available therapy… read more here.
Keywords: response; bat; rux; hct control ... See more keywords
Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124176
Abstract: Introduction: Preclincal murine models of primary and secondary hemophagocytic lymphohistiocytosis (HLH) have demonstrated the role of JAK/STAT signaling in propagating the cytokine-mediated hyperinflammatory state. Das et al. (Blood 2016) demonstrated that ruxolitinib (rux) effectively attenuates… read more here.
Keywords: ruxolitinib; rux; treatment; bid ... See more keywords
The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-129112
Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a severe immunologic syndrome characterized by a failure of CD8 T-cells to appropriately terminate immune responses, leading to excessive activation of immune cells that mediate life-threatening organ damage. Many patients with… read more here.
Keywords: cd8 cells; dex; resistance; hlh ... See more keywords
Simulated Treatment Comparison (STC) of Human Mesenchymal Stromal Cells (Remestemcel-L, REM) and Ruxolitinib (RUX) for Steroid-Refractory Acute Graft-Versus-Host Disease (SR aGVHD) Pediatric Patients
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-131098
Abstract: Introduction: Allo-HSCT was performed on 1771 US children in 2016. SR aGVHD is a life-threatening complication of allo-HSCT associated with substantial healthcare costs and significant reductions in pediatric QOL. Grade II-IV aGVHD occurs in 39-59%… read more here.
Keywords: trial; rux; age; rem ... See more keywords
Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136673
Abstract: Introduction: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by cytopenia, splenomegaly, and debilitating constitutional symptoms, such as fatigue, night sweats, weight loss, bone pain, and pruritus. Prior to the approval of the selective Janus kinase-2… read more here.
Keywords: rec rux; research; rux; aty rux ... See more keywords
Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139281
Abstract: BACKGROUND RUX, a JAK 1/2 inhibitor, is a second-line treatment for symptom management and control of trilineage expansion in patients (pts) with PV who are resistant or intolerant to hydroxyurea (HU). In the RESPONSE study,… read more here.
Keywords: bat; speakers bureau; response; hct control ... See more keywords
Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-140820
Abstract: Background The myeloproliferative neoplasm myelofibrosis (MF) is associated with reduced overall survival (OS) compared with the general population (Hultcrantz M, et al. J Clin Oncol. 2012;30[24]:2995-3001; Price GL, et al. PLoS One. 2014;9[3]:e90299). The Janus… read more here.
Keywords: research funding; rux; rux approval; approval ... See more keywords
Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood-2022-158678
Abstract: Introduction: Patients (pts) with primary and secondary myelofibrosis (MF) have a reduced life expectancy. While several oral Janus Kinase (JAK)-1/2 inhibitors such as ruxolitinib (RUX) have demonstrated improvements in symptom burden and spleen volume reduction… read more here.
Keywords: combination; rux; abemaciclib; phase ... See more keywords